Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab plus platinum-doublet chemotherapy as neoadjuvant therapy for resectable SMARCA4-deficient non-small cell lung cancer
ChiCTR2600132806Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Oct 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in non-small cell lung cancer (NSCLC), sponsored by Shandong Cancer Hospital. Primary endpoint: Pathological complete response rate. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600132806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132806.